Search

Search results

179 results found

Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease.

Papamichael, Konstantinos, Niels Vande Casteele, Bincy P Abraham, Timothy Ritter, Anjali Jain, and Adam S Cheifetz. 2023. “Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease.”. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 21 (11): 2978-2980.e2.

Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-analysis.

Trivedi, Hirsh D, Emily W Lopes, Jeremy Glissen Brown, Shaan Dudani, Michelle Lai, Joseph D Feuerstein, and Theodore T Pierce. 2023. “Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.”. Journal of Clinical Gastroenterology 57 (6): 610-16.

A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.

Cheifetz, Adam S, Maria T Abreu, Waqqas Afif, Raymond K Cross, Marla C Dubinsky, Edward Loftus V, Mark T Osterman, et al. 2021. “A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.”. The American Journal of Gastroenterology 116 (10): 2014-25.